Immunicum AB (publ) Clarifies Information Regarding Directed Issue
October 16 2018 - 10:45AM
Press Release
16 October 2018
NOT FOR RELEASE, DISTRIBUTION OR
PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES
OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN
WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE
UNLAWFUL
Immunicum AB (publ) Clarifies Information Regarding Directed Issue
As communicated
earlier today the board of directors of Immunicum AB (publ) has
decided to implement a directed issue of approximately SEK 178M and
a Rights Issue of approximately SEK 173M. Both issues are subject
to approval by the Extraordinary General Meeting on 8 November
2018.
The directed issue comprises of
20,915,588 shares issued at a price of SEK 8.50 per share. The
issue has been subscribed by, essentially, a number of
institutional investors including the Fourth AP-fund (SEK 38M),
Gladiator, (SEK 32M), the Second AP-fund (SEK 21M), Alfred Berg
(SEK 20M), Nordic Cross (SEK 17M) and Adrigo (SEK 10M). In
addition, a number of private investors have subscribed for the
directed share issue including Rothesay (SEK 10M), Lennart Sten
through company (SEK 7.5M), EWS Stiftelsen (SEK 3M) and JESEM AS
(SEK 1M). Furthermore, a number of private investors have
subscribed for SEK 18M through Avanza Pension.
The reason for deviating from the
shareholders' pre-emption rights is that the board finds it
beneficial for Immunicum's future development to strengthen the
ownership base with a number of strategical and long-term
shareholders, as well as taking advantage of the opportunity to
provide the company with additional capital on favorable terms.
The newly issued shares in the
directed issue are expected to be admitted to trading on Nasdaq
Stockholm at the same time as the shares from the Rights Issue. The
shares subscribed for and issued in the directed issue does
therefore not qualify for participation in the Rights Issue.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO,
Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer and Joanne
Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
This information
is information that Immunicum (publ) is obliged to make public
pursuant to Nasdaq Stockholm's Rule book for Issuers. The
information was submitted for publication, through the agency the
contact person set out above, at 4.45 pm CET on 16 October
2018.
Important
information
The information in this press release does not constitute an offer
to acquire, subscribe or otherwise trade in shares or other
securities issued by Immunicum AB (publ). Invitation to interested
parties to subscribe for shares in Immunicum will only be made
through the prospectus that Immunicum will publish.
The information in this press
release may not be released, published, reproduced or distributed
in or to the United States, Canada, Japan, Australia, Hong Kong,
Switzerland, Singapore, South Africa or New Zealand or any other
country or jurisdiction where such action is not permitted or where
such action is subject to legal restrictions or would require
further registration or other measures than what is required by
Swedish law. Measures contrary to this instruction may constitute a
breach of applicable securities legislation.
No shares have been registered,
and will not be registered, in accordance with the United States
Securities Act from 1933 ("Securities Act") and may not be offered,
subscribed, sold or transferred, directly or indirectly, within the
United States except after written approval from Immunicum and
under an applicable exemption from the registration requirements of
the Securities Act and in accordance with securities legislation in
the relevant state or any other jurisdiction in the United
States.
About Immunicum AB
(publ)
Immunicum is establishing a unique
immuno-oncology approach through the development of allogeneic,
off-the-shelf cell-based therapies. Our goal is to improve survival
outcomes and quality of life by priming the patient's own immune
system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the
potential to become a backbone component of modern cancer
combination treatments in a variety of solid tumor indications.
Founded and based in Sweden, Immunicum is publicly traded on the
Nasdaq Stockholm www.immunicum.com
20181016_Immunicum Clarifies
Information Directed Issue_ENG
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024